Re: earnings
P2 took a huge hit Q/Q and Y/Y (this has to be the most alarming news as P2 was the main attraction to any outside buyer).
Krystexxa has good data showing T3 protocols have reduced on-site reactions to less than 1% (this should result in a greatly increased available population for treatment).
Company is still struggling. Non-GAAP tax rate is almost 50% (drop in PC sales has greatly affected the tax mix).
Bright spot is they did manage to increase cash reserves to $650M which reduces the real debt to under $1.4B. They have to acquire more late stage drugs or perish, which they will certainly do.
Second bright spot is an increase in Actimmune organic sales. Cancer trials data is the only thing I can think of that could pop the stock price, and certainly could happen.
Three bright spots (including encouraging Krystexxa data), but overall a dark background.